BioLineRx Ltd. (BLRX) Q2 2026 Earnings Call Transcript

BioLine Rx (NASDAQ:BLRX) reported quarterly sales of $294.000 thousand which missed the analyst cons

- Second of five planned cohorts ongoing in Phase 1/2a trial of GLIX1 in GBM; third patient cohort e

Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 41.4% to $7.29 during Friday's pre-mark

BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a clinical

TEL AVIV, Israel, Aug. 28, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLine

Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel, Aug. 25, 2026 /PRNewswire/ --

Presentation Details:Title: GLIX1, a TET2 Activator Targeting the DNA Damage Response, Synergizes wi

TEL AVIV, Israel and OSLO, Norway, July 20, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE

Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 55.8% to $1.11 during Wednesday'

Synergy was demonstrated in a combination arm of GLIX1 and the PARP inhibitor olaparib at low doses,

Synergy was demonstrated in a combination arm of GLIX1 and the PARP inhibitor olaparib at low doses,

BioLineRx Ltd. (BLRX) Q1 2026 Earnings Call Transcript

BioLine Rx (NASDAQ:BLRX) reported quarterly sales of $477.000 thousand which beat the analyst consen

- Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma

BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-

TEL AVIV, Israel and OSLO, Norway, May 22, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE:

Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel, May 20, 2026 /PRNewswire/ -- B

BioLineRx shares new GLIX1 glioblastoma data showing anti-tumor activity, including in temozolomide-

GBM remains one of the most aggressive and treatment-resistant cancers, urgently in need of breakthr

New preclinical data further demonstrate GLIX1's robust efficacy in a dose-dependent manner, with st

The GLIX1 program is being conducted under a collaboration between BioLineRx and Hemispherian announ

Patient was dosed at NYU Langone Health under the supervision of Dr. Alexandra Miller, Chief of Neur

OSLO, Norway--(BUSINESS WIRE)--Hemispherian AS, a clinical-stage oncology company developing novel s

BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pu

GLIX1, a TET2 activator ,  is a first -in- class , oral, small molecule targeting DNA damage respons

BioLine Rx (NASDAQ:BLRX) reported quarterly losses of $(0.34) per share which beat the analyst conse

BioLineRx Ltd. (BLRX) Q4 2025 Earnings Call Transcript

BioLine Rx (NASDAQ:BLRX) reported quarterly sales of $194.000 thousand which missed the analyst cons

- On track to initiate Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) by end

BioLineRx (NASDAQ: BLRX - Get Free Report) is expected to release its Q4 2025 results before the mar

BioLineRx Ltd. (NASDAQ: BLRX) to release Q4 earnings on March 23. Previous Q3 losses were 22 cents p

BioLineRx Ltd. (NASDAQ: BLRX) to release Q4 earnings on March 23. Previous Q3 losses were 22 cents p

Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel, March 16, 2026 /PRNewswire/ --

https://ir.biolinerx.com/static-files/e6f7cf56-4605-44e6-8ed9-f0738b67b983

BioLine Rx (NASDAQ:BLRX) reported quarterly losses of $(0.22) per share which beat the analyst conse

BioLineRx Ltd. ( BLRX ) Q3 2025 Earnings Call November 24, 2025 8:30 AM EST Company Participants Iri

- Establishes joint venture with Hemispherian AS to advance GLIX1, a first-in-class, oral, small mol

- GLIX1 restores TET2 activity in cancer, resulting in double stranded DNA breaks in cancer cells on